Navigation Links
Cell Genesys to Webcast Third Quarter 2007 Conference Call
Date:10/25/2007

SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's third quarter financial results that will be broadcast live over the internet on Thursday, November 1, 2007, at 2:00 p.m. PT/ 5:00 p.m. ET.

The webcast will be available on the investor relations section of the company's website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, the call will be archived on the website for at least 72 hours following the call. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at '/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Sonic Foundry to Webcast Bridge Arch Floating Down Mississippi
2. Visions: Broderick says Wisconsin should be in top third in venture capital
3. Third Wave files countersuit vs. Digene in patent case
4. Third Wave reports net loss of $18.9M for 2006
5. Stratagene to pay Third Wave $10.75M in patent case
6. Third Wave responds to Digene patent lawsuit
7. Third Wave seeks approval of Cystic Fibrosis test
8. Third Wave Technologies to raise $14.9M through private debt
9. Venture capital above $6B for third straight quarter
10. Third Wave reports $5.2M third quarter loss
11. Third Wave reports another loss, stronger sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...itzerland, Dec. 4 Octapharma,Chai...s D. Curtin has been,selected to lead Octapharma,...had been Octapharma,s U.S. legal counsel since 200...utics, Inc. , The largest private plasma pr...acquired Life Therapeutics, the Atlanta company th...
(Date:12/4/2008)...wswire-FirstCall/ -- NeoStem, Inc.,(NYSE Alternex...llection,processing and long-term storage of adu...unced that it has reached a major milestone in its...rst ever collection center for collection of,adul...cal need in New York,City and has chosen Bruce Ya...
(Date:12/4/2008)...Newswire/ -- Azur Pharma Limited ("Azur") today,a...eement with BioSante,Pharmaceuticals, Inc ("BioSa...Elestrin(TM). Elestrin is a fast drying gel formul...atment of moderate to severe vasomotor symptoms,a... the U.S. Food and Drug,Administration ("FDA") in...
(Date:12/4/2008)...PRNewswire/ -- Parion Sciences, Inc. today announc...ILD ), has initiated a Phase I,clinical trial of ...y and,tolerability of the investigational compoun...on for the treatment of pulmonary disease. Previo...um channel (ENaC) blocker discovered by,Parion, a...
Breaking Biology Technology:Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 2NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 3NeoStem's New York City Adult Stem Cell Collection Center Has Opened and Begun Collections 4Azur Pharma Ltd. Enters Into Definitive Agreement With BioSante Pharmaceuticals Inc [nasdaq: BPAX], to Acquire U.S. Rights to Elestrin (TM) 2Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 2Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411 3
... - A new 75,000-square-foot facility in the Dodge...room for an expanding healthcare technology compan...on 28 acres in the industrial park to replace two ...d. It moved into the new space in April. The new b...ated Peripherals Inc., more than twice the space a...
...lumn, I reviewed some of the key findings of a stu...nces of 25 of the largest practitioners of outsour...findings from another study conducted by the consu...roviders of IT outsourcing services. The complete ... third consecutive year that DiamondCluster has po...
...etavante Corp , the financial technology subsidiar...quisition, announced in June, of Herndon, Va.-base...nd consulting services to the financial industry. ...port management software in both lending and depos... Advanced Financial Solutions (AFS), a Metavante c...
...s. - The University of Wisconsin-Whitewater has r... line, developing what is now known as the Informa...gram, the successor the previously offered Compute...oint work between the school and the business sect... far greater emphasis than its predecessor on netw...
Other Biology Technology:Is outsourcing reaching its limits or simply pausing for breath? - Part II 2Is outsourcing reaching its limits or simply pausing for breath? - Part II 3Is outsourcing reaching its limits or simply pausing for breath? - Part II 4Whitewater upgrades tech degree program 2Whitewater upgrades tech degree program 3
(Date:12/3/2008)...e December 14-17, 2008 at the University,s Sede Bo...es of BGU,s Jacob Blaustein Institutes for Desert ...ference are the United Nations Educational, Scient...Ministry for Foreign Affairs, Jewish National Fund...lobal leader in smart water solutions for agricult...
(Date:12/3/2008)...arded as safe for pregnancy - other asthma drugs h...n usually keep using the same asthma drugs they we...ys are the best studied and can be regarded as saf...cessary however. According to the German Institute..., more data from trials could reassure women who w...
(Date:12/3/2008)... promises to enable cheap, lifesaving new drugs to...malaria, and to create innovative biofuels that ca... science and its applications are raising question...se scientists purposely changing the definition of...unintentionally equipping terrorists with frighten...
(Date:12/2/2008)...encing is easier than ever, but the amount of data...puter program now shows that genome sequence analy... researchers find hidden relationships in massive ...ent of Energy,s Pacific Northwest National Laborat... Supercomputing ,08 High Performance Computing Ana...
Breaking Biology News(10 mins):Ben-Gurion University of the Negev to host 2Pregnant women with asthma can be more confident about some medicines 2Synthetic biology: Is ethics a showstopper? 2PNNL researchers earn top honors at Supercomputing conference 2PNNL researchers earn top honors at Supercomputing conference 3Stanford Accelerates Union Busting Tactics 24694 1Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday August 6 2008 6838 1Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday August 6 2008 6838 2Alexza to Announce 2008 Second Quarter Financial Results and Update Its Clinical Pipeline on Wednesday August 6 2008 6838 3Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 1Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 2Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 3Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 4Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 5Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 6Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 7Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 8Neurocrine Biosciences Reports Second Quarter 2008 Results 6833 9Phase II Data on Lillys Antibody Show It Affects Amyloid Beta a Protein Believed To Be Associated with Alzheimers Disease 2756 1Phase II Data on Lillys Antibody Show It Affects Amyloid Beta a Protein Believed To Be Associated with Alzheimers Disease 2756 2Phase II Data on Lillys Antibody Show It Affects Amyloid Beta a Protein Believed To Be Associated with Alzheimers Disease 2756 3Phase II Data on Lillys Antibody Show It Affects Amyloid Beta a Protein Believed To Be Associated with Alzheimers Disease 2756 4Phase II Data on Lillys Antibody Show It Affects Amyloid Beta a Protein Believed To Be Associated with Alzheimers Disease 2756 5Phase II Data on Lillys Antibody Show It Affects Amyloid Beta a Protein Believed To Be Associated with Alzheimers Disease 2756 6
...in exploring the potential future use of stem cell...ticle in the current issue of Nature (June 29, 200...scular Disease Director Deepak Srivastava, MD, and... Ivey, PhD, the paper cites a better understanding...mental processes within the heart that can be repr...
...overed that the human immunodeficiency virus, the ... to destroy it by hiding out in the mucosal tissue...nues to replicate in the gut mucosa, suppressing i...retroviral therapy--even when blood samples from t...rking. Results of the three-year study appear in t...
... Mesopotamian marshes since 2003 has resulted in a...vertebrates, plants, fish, and birds, according to...rtis J. Richardson of Duke University and Najah A....t fieldwork conducted over the past two years in f...r inflow from the Tigris and Euphrates rivers has ...
... agencies have concluded that the ozone hole over ...years later than previously believed. , Researcher...Administration (NOAA) and the National Center for ...ool, a math-based computer model, to predict the t...be published tomorrow in Geophysical Research Lett...
Other Biology News:Progress being made in exploring potential use of stem cells to treat heart disease 2UC Davis study finds HIV hiding from drugs in gut, preventing immune recovery 2UC Davis study finds HIV hiding from drugs in gut, preventing immune recovery 3Iraq's marshes show progress toward recovery 2Scientists find Antarctic ozone hole to recover later than expected 2Scientists find Antarctic ozone hole to recover later than expected 3
...lvement of integrins in vascular proliferation, ad.... The integrin family of cell adhesion receptors c...imers, composed of an a and b subunit that associa...ctional diversity of the integrin family are based...
...ep ion exchange media are rigid macroporous hydrop...flow rates at moderate pressures, while the macrop... hydrophilic matrix reduces nonspecific binding. M... anion exchanger with very high flow rates and res...
siTrio siRNA --- a cocktail of 3 siRNAs specifically targeted to your target gene of interestis our most popular product. The siTrio reagent guarantees you get more than 75% knockdown of your target
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112
Biology Products: